A 12 Week, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus

Trial Profile

A 12 Week, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Mirodenafil (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Sponsors SK Chemicals
  • Most Recent Events

    • 14 Sep 2010 Status changed from recruiting to completed according to publication of results in the Journal of Sexual Medicine.
    • 01 Aug 2010 Results were published in the Journal of Sexual Medicine.
    • 19 Mar 2009 Results reported at the 24th Congress of the European Association of Urology (EAU), 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top